Effect of oridonin-mediated hallmark changes on inflammatory pathways in human pancreatic cancer (BxPC-3) cells

Ru-Yi Chen, Bin Xu, Su-Feng Chen, Si-Si Chen, Ting Zhang, Jun Ren, Jian Xu

Ru-Yi Chen, Su-Feng Chen, Si-Si Chen, Ting Zhang, Jun Ren, Jian Xu, The College of Life Science, Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang Province, China; Bin Xu, Department of General Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China

Author contributions: Chen RY, Xu B, Chen SF, Chen SS, and Xu J were involved in creating the study, conducting the experiments, data analysis, manuscript preparation and revision; Zhang T and Ren J were involved in the data analysis and critical manuscript revision.

Supported by The Qianjiang Talent Project of Zhejiang Province, No. 2013R10072; and the Natural Science Foundation of Zhejiang Province, Nos. LY14H160037 and LY12H16007

Correspondence to: Jian Xu, PhD, Associate Professor, The College of Life Science, Zhejiang Chinese Medical University, Bin Wen Road, Bin Jiang District, Hangzhou 310053, Zhejiang Province, China.
xujian832002@163.com

Telephone: +86-571-86633001 Fax: +86-571-86613600

Received: May 2, 2014 Revised: June 29, 2014 Accepted: July 16, 2014 Published online: October 28, 2014

Abstract

AIM: To investigate the effect of oridonin on nuclear transcription factors and to study the relationship between biological behavior and inflammatory factors in human pancreatic cancer (BxPC-3) cells.

METHODS: BxPC-3 cells were treated with various concentrations of oridonin, and viability curves were generated to test for inhibitory effects of the drug on cells. The expression of cytokines such as interleukin-1β (IL-1β), IL-6, or IL-33 was detected in BxPC-3 cell supernatants using an enzyme-linked immunosorbent assay (ELISA), and the protein expression of nuclear transcription factors including nuclear factor κB, activating protein-1, signal transducer and activator of transcription 3, bone morphogenetic protein 2, transforming growth factor β1 and sma and mad homologues in BxPC-3 cells was detected using Western blot. Carcinoma hallmark-related proteins such as survivin, vascular endothelial growth factor, and matrix metalloproteinase 2 were also detected using immunoblotting, and intra-nuclear IL-33 expression was detected using immunofluorescent staining.

RESULTS: Treatment with oridonin reduced the viability of BxPC-3 cells in a dose dependent manner. The cells exhibited reduced growth following treatment with 8 μg/mL oridonin (13.05% ± 3.21%, P < 0.01), and the highest inhibitory ratio was 90.64% ± 0.70%, which was achieved with oridonin at a dose of 32 μg/mL. The IC50 value of oridonin in BxPC-3 cells was 19.32 μg/mL. ELISA analysis revealed that oridonin down-regulated the inflammatory factors IL-1β, IL-6, and IL-33 in a dose-dependent manner. IL-1β expression was significantly reduced in the 16 and 32 μg/mL treatment groups compared to the control group (12.97 ± 0.45 pg/mL vs 14.40 ± 0.38 pg/mL, P < 0.01). Similar trends were observed for IL-6 expression, which was significantly reduced in the 16 and 32 μg/mL treatment groups compared to the control group (12.97 ± 0.45 pg/mL vs 14.40 ± 0.38 pg/mL, P < 0.01). IL-33 expression was significantly reduced in the 8, 16, and 32 μg/mL treatment groups compared to the control group (911.05 ± 14.18 pg/mL vs 945.25 ± 12.09 pg/mL, P < 0.01). 911.05 ± 14.18 pg/mL vs 945.25 ± 12.09 pg/mL, P < 0.01. Similar trends were observed for IL-6 expression, which was significantly reduced in the 16 and 32 μg/mL treatment groups compared to the control group (911.05 ± 14.18 pg/mL vs 945.25 ± 12.09 pg/mL, P < 0.01). IL-33 expression was significantly reduced in the 16 and 32 μg/mL treatment groups compared to the control group (911.05 ± 14.18 pg/mL vs 945.25 ± 12.09 pg/mL, P < 0.01). IL-33 expression was significantly reduced in the 16 and 32 μg/mL treatment groups compared to the control group (911.05 ± 14.18 pg/mL vs 945.25 ± 12.09 pg/mL, P < 0.01).

CONCLUSION: The results obtained suggest that oridonin alters the hallmarks of pancreatic cancer cells through the regulation of nuclear transcription factors.
Oridonin, which has been extracted from Radix scutellariae, is a tetracyclic diterpenoid compound. Structural and pharmacological studies indicate that oridonin is one of the most important therapeutic compounds found in Radix scutellariae, due to its heat-clearing, detoxifying, anti-inflammatory, anti-nociceptive, and anti-tumorigenic properties[7]. Hanahan and Weinberg[6] revisited the original hallmarks of cancer and considered tumor-promoted inflammation to be included in this list. Few papers have focused on the anti-tumor mechanism of oridonin and, in particular, on its anti-inflammatory effect in pancreatic cancer. In a previous study, we found that oridonin inhibited the growth of human pancreatic cancer (BxPC-3) cells and down-regulated the mRNA expression of interleukin-1β (IL-1β), IL-6, IL-33, and bone morphogenetic protein-2 (BMP-2)[7]. Therefore, we proposed that oridonin could regulate the association of inflammatory factors with the tumor microenvironment (by altering related pathways) and modify nuclear transcription factors, thereby modulating the expression of downstream target genes and, in turn, changing cancer hallmarks.

INTRODUCTION
Pancreatic cancer is a common cancer of the digestive system and is a leading cause of morbidity and mortality worldwide. In this report, we demonstrate that oridonin is able to inhibit the growth of human pancreatic cancer (BxPC-3) cells and change the expression of cancer hallmark-related proteins. Inflammatory factors were decreased in BxPC-3 cells treated with oridonin, and oridonin also regulated nuclear transcription factor pathways. We propose that oridonin can reduce growth, metastasis, and angiogenesis in BxPC-3 cells by regulating the nuclear transcription factor-mediated expression of related inflammatory factors.

MATERIALS AND METHODS
Cell line and culture conditions
The human pancreatic cancer cell line BxPC-3 was supplied by the Shanghai Institute of Biological Sciences of the Chinese Academy of Sciences and was maintained as a monolayer culture in RPMI1640 (GIBCO, NY, United States) medium supplemented with 10% fetal bovine serum at 37 ℃ in a humidified atmosphere containing 5% CO2.

Cell viability assay
Cell viability was quantified using a short-term microculture tetrazolium (MTT, Sigma, United States) assay. In a 96-well microplate (the outer wells were left empty for the later addition of water), $5 \times 10^4$ cells per well were treated with 2, 4, 8, 16, 32, 64, or 128 μg/mL of oridonin (Xiya Chemtech Co., Chengdu) for 24 h. As a negative control, cells were treated with 0.1% dimethyl sulfoxide (DMSO), the same DMSO concentration used for drug delivery. After treatment, the media was replaced with 180 μL of serum-free medium and 20 μL of MTT solution (5 mg/mL in sterile phosphate-buffered saline). After a 4-h incubation at 37 ℃, the MTT solution in the wells was replaced with 150 μL DMSO. The absorption at 570 nm ($A_{570}$) was measured using a microplate reader (Bio-Rad, Model 680, United States), and the results are expressed as the percentage of cell viability. The IC50 value was calculated as the concentration of oridonin that inhibited cell growth by 50%. The percentage of cell viability was calculated based on the following equation: Viability ratio % = $A_{570\text{control}} / A_{570\text{treatment}} \times 100\%$. Each assay was performed at least three times.

Detection of IL-1β, IL-6, and IL-33 production
Secretion of IL-1β, IL-6, or IL-33 in response to treatment of cells with oridonin (0, 8, 16, or 32 μg/mL) was determined using a bioassay. Briefly, culture supernatants of BxPC-3 cells were collected at 24 h post-treatment and cleared of cell debris by brief centrifugation. IL-1β, IL-6, and IL-33 levels were measured using human enzyme-linked immunosorbent assay (ELISA) kits (Human interleukin 1β ELISA Kit,CUSABIO,CSB-E08053h; Human interleukin 6 ELISA Kit, Cusabio, CSB-E04638h; Human interleukin 33 ELISA Kit, Cusabio, CSB-E13000h) according to the manufacturer's instructions. The absorbance was measured at 490 nm using a microplate reader.
**Immunofluorescence staining**

For immunofluorescence experiments, cells were plated onto glass coverslips one day before treatment with oridonin (0, 8, 16, or 32 μg/mL) for 24 h. Cells were fixed in acetone for 30 min and incubated with an antibody raised against IL-33 (Santa Cruz Biotechnology, sc98660, United States) in PBS containing 2% FBS for 2 h. After three washes with PBS, the samples were incubated with the appropriate secondary antibody for 1 h in PBS containing 2% FBS and washed again as described above. Finally, the coverslips containing the cells were incubated with DAPI (0.5 μg/mL) for 1 min, and images were obtained using a fluorescence microscope.

**Western blot analysis**

To detect various proteins, BxPC-3 cells treated with oridonin (0, 8, 16, or 32 μg/mL) were washed twice with PBS and then lysed in RIPA lysis buffer (1% Triton X-100, 0.1% SDS, and 1% sodium deoxycholate). The lysates were then centrifuged, and the supernatants were collected. Protein concentrations were quantitated using a bicinchoninic acid assay kit (MultiSciences Biotech, PQ0011, China). Protein extracts (40 μg) were resolved using 10%-15% sodium dodecyl sulfate polyacrylamide gel electrophoresis. After transferring the proteins to membranes, the membranes were blocked using 5% nonfat dry milk for 2 h at room temperature and incubated overnight with primary antibodies raised against C-Jun (Bioworld, BS1737, United States), nuclear factor κB (NF-κB)1 (Abcam, ab32360, United States), RelA (Abcam, ab31481, United States), phosphorylated RelA (P-RelA, ab106129, United States), signal transducer and activator of transcription 3 (STAT3) (Abcam, ab50761, United States), phosphorylated STAT3 (P-STAT3, Abcam, ab76315, United States), transforming growth factor β1 (TGFβ1) (Abcam, ab64715, United States), BMP-2 (Bioworld, BS3473, United States), Smad2 (Abcam, ab33875, United States), phosphorylated Smad2 (P-Smad2, Abcam, ab53100, United States), Smad3 (Abcam, ab40854, United States), phosphorylated Smad3 (P-Smad3, Cell Signaling Technology, C25A9, United States), Smad4 (Abcam, ab40759, United States), phosphorylated Smad1/5/8 (P-Smad1/5/8, Cell Signaling Technology, 9511S, United States), Smad6 (Abcam, ab63713, United States), Smad7 (Abcam, ab124890, United States), vascular endothelial growth factor (VEGF) (Abcam, ab46154, United States), survivin (Abcam, ab76424, United States), MMP-2 (Abcam, ab86607, United States), and β-actin (MultiSciences, Mab1445, China) at 4 °C. The membranes were then incubated with secondary antibodies conjugated with horseradish peroxidase (goat anti-mouse IgG, MultiSciences Biotech, GAM0072, China) or goat anti-rabbit IgG, MultiSciences Biotech, GAR0072, China) for 2 h at room temperature. The membranes were then developed using an ECL substrate kit (MultiSciences Biotech, P1425, China) and visualized using an Omega Lum G imaging system. The amount of protein present was normalized against β-actin. Image J software was used to quantify the bands.

**Statistical analysis**

For comparisons between the treatment groups, one-way analysis of variance was performed. The data are presented as mean ± SD in each figure. Statistical analyses were performed using the SPSS (Statistical Package for the Social Sciences) statistical package, version 17.0. The Mann-Whitney rank test was used to compare different groups. A P value less than 0.05 was considered statistically significant.

**RESULTS**

**Oridonin-mediated hallmark changes in BxPC-3 cells**

To investigate the possible effect of oridonin on changes in hallmarks in BxPC-3 cells, cells were treated with various concentrations of oridonin for 24 h. As shown in Figure 1A, oridonin induced BxPC-3 cell death in a dose-dependent manner. At low doses, oridonin did not show any inhibitory effect on BxPC-3 cells. No significant differences were observed between the negative control and the low-dose treatment (2 and 4 μg/mL) groups. Growth was inhibited in BxPC-3 cells following treatment with 8 μg/mL (13.05% ± 3.21%, P < 0.01) oridonin compared to without treatment. When treated with 16 μg/mL oridonin, the cell death rate was nearly 50%, and the IC50 of oridonin was determined to be 19.32 μg/mL in the BxPC-3 cell line. The highest inhibitory ratio was 90.64% ± 0.70% (obtained using 32 μg/mL oridonin). We next examined the effect of oridonin on the expression of hallmark-related proteins in BxPC-3 cells. BxPC-3 cells were treated with oridonin at 0, 8, 16, or 32 μg/mL for 24 h, and we observed that 8, 16, and 32 μg/mL oridonin caused obvious decreases in the expression of survivin, VEGF, and MMP-2 (Figure 1B).

**Oridonin down-regulates expression of proteins in the NF-κB/AP-1 pathway**

We next investigated the effect of oridonin on NF-κB/AP-1-dependent protein expression, including the expression of IL-1β, IL-33, NF-κB1, RelA, P-RelA, and AP-1. BxPC-3 cells were treated with 0, 8, 16, or 32 μg/mL oridonin for 24 h. The ELISA results showed that treatment of BxPC-3 cells with 8, 16, or 32 μg/mL oridonin altered the expression of IL-1β and IL-33 in a dose-dependent manner (Figure 2A and B). IL-1β expression was significantly reduced in the 16 and 32 μg/mL treatment groups compared to the negative control group (12.97 ± 0.45 pg/mL, 11.17 ± 0.63 pg/mL vs 14.40 ± 0.38 pg/mL, P < 0.01). Similar trends were observed for IL-33 expression, which was significantly reduced in the 8, 16, and 32 μg/mL treatment groups compared to the negative control group (911.05 ± 14.18 pg/mL vs 945.25 ± 12.09 pg/mL, P < 0.01). These trends were also observed for NF-κB1, RelA, P-RelA, and AP-1 expression. Western blot analysis showed that the protein expression. Western blot analysis showed that the protein
expression levels of NF-κB1, RelA, P-RelA, and AP-1 decreased as the concentration of oridonin increased (Figure 2C).

**Oridonin reduces the nuclear expression of IL-33**

To determine the effect of oridonin on nuclear IL-33 expression, BxPC-3 cells were treated with 0, 8, or 32 μg/mL of oridonin for 24 h. Immunofluorescence staining analysis (Figure 2D) showed that the control group retained intact cell nuclei and exhibited obvious green fluorescence, indicating a high level of IL-33 expression in both the nucleus and the cytoplasm. Interestingly, the green fluorescence was significantly and dose-dependently decreased in the nuclei of BxPC-3 cells following treatment with 8 and 32 μg/mL oridonin. Additionally, the nuclei of oridonin-treated BxPC-3 cells were broken or disintegrated and exhibited only minor levels of fluorescence.

**Oridonin exerts a negative effect on the STAT3 pathway**

To investigate the effect of oridonin on STAT3-driven protein expression, including that of IL-6, STAT3, and P-STAT3, BxPC-3 cells were treated with 0, 8, 16, or 32 μg/mL oridonin for 24 h. The ELISA results showed that treatment of BxPC-3 cells with 8, 16, or 32 μg/mL oridonin significantly and dose-dependently decreased the expression of IL-6 (Figure 3A). IL-6 expression was significantly reduced in the 16 and 32 μg/mL treatment groups compared to the negative control group (4.05 ± 0.14 pg/mL vs 4.45 ± 0.43 pg/mL, P < 0.05; 3.95 ± 0.13 pg/mL vs 4.45 ± 0.43 pg/mL, P < 0.01). Similar trends were observed for STAT3 and P-STAT3 (P-STAT3) expression. Western blot analysis showed that the protein expression levels of STAT3 and P-STAT3 decreased as the concentration of oridonin increased (Figure 3B). These results indicate that oridonin-mediated reductions in IL-6 levels might be regulated through the STAT3 signaling pathway.

The effect of oridonin on Smads is related to the TGFβ1 and BMP2 pathways

To characterize whether the effect of oridonin on protein expression is mediated by the TGFβ and Smad signaling pathways, BxPC-3 cells were treated with 0, 8, 16, or 32 μg/mL oridonin for 24 h. Western blot results showed that the protein expression levels of TGFβ1, BMP-2, Smad2/3/6/7, and P-Smad1/2/3/5/8 decreased as the concentration of oridonin increased. Oridonin down-regulated TGFβ1, BMP-2, Smad2/3/6/7, and P-Smad1/2/3/5/8 but increased the expression of Smad4 (Figure 4).

**DISCUSSION**

Oridonin is one of the most effective antitumor agents obtained from Rabdosia rubescens and exhibits antitumor activity against a number of cancer cell types[9]. The results obtained in this study demonstrate that oridonin inhibits the growth of human BxPC-3 pancreatic cancer cells, consistent with previous data. It is known that survivin, VEGF, and MMP-2 play important biological roles in pancreatic cancer growth, angiogenesis, and metastasis, respectively. Our results also indicate that oridonin specifically inhibits the expression of survivin, VEGF, and MMP-2.

In addition, tumor-promotion inflammation is also a hallmark of cancer. Cytokines are important inflammatory mediators that regulate a wide range of processes involved in cancer pathogenesis[10]. We could find that IL-1β, IL-33, IL-6, TGF-β1 and BMP2 were decreased by oridonin treatment. Pancreatic cancer can express receptors on the cell surface, such as IL1R[11], ST2[12], IL6R[13] and TGFR[14], that are activated by specific cytokines. These signaling pathways can regulate cellular growth, differentiation, proliferation and apoptosis. Jones et al[15]...
Figure 2  Oridonin decreases both the expression of the nuclear factors nuclear factor κB/activating protein-1/interleukin-33 in BxPC-3 cells and the release of interleukin-1β and interleukin-33 into the supernatant. A and B: Enzyme-linked immunosorbent assay analysis of the effect of oridonin on interleukin (IL)-1β and IL-33 in BxPC-3 cells. Data are expressed as mean ± SD. *P < 0.05, **P < 0.01 vs the control treatment; C: Western blot analysis of the effect of oridonin on the levels of signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 in BxPC-3 cells treated with 0, 8, 16, or 32 μg/mL oridonin for 24 h. Three independent experiments were performed, and a representative result is shown; D: Immunofluorescent staining analysis of the effect of oridonin on IL-33 in BxPC-3 cells (× 100). The BxPC-3 cells were treated with 0, 8, or 32 μg/mL oridonin for 24 h. NF-κB: Nuclear factor κB.
Western blot analysis of the effect of oridonin on proteins in the Smad signaling pathway in BxPC-3 cells. The BxPC-3 cells were treated with 0, 8, 16, or 32 μg/mL oridonin for 24 h. Three independent experiments were performed, and a representative result is shown.

**Figure 3** Oridonin reduces both the expression of signal transducer and activator of transcription 3 in BxPC-3 cells and the release of interleukin-6 into the supernatant. A: Enzyme-linked immunosorbent assay analysis of the effect of oridonin treatment on interleukin (IL)-6 in BxPC-3 cells. Data are expressed as mean ± SD. *P < 0.01 vs the control treatment; B: Western blot analysis of the effect of oridonin treatment on the levels of signal transducer and activator of transcription 3 (STAT3) and phospho-STAT3 in BxPC-3 cells treated with 0, 8, 16, or 32 μg/mL oridonin for 24 h. Three independent experiments were performed, and a representative result is shown.

**Figure 4** Oridonin regulates the expression of proteins in the transforming growth factor β (TGF-β)/Smad pathway. Western blot analysis of the effect of oridonin on proteins in the Smad signaling pathway in BxPC-3 cells. The BxPC-3 cells were treated with 0, 8, 16, or 32 μg/mL oridonin for 24 h. Three independent experiments were performed, and a representative result is shown.

found that pancreatic cancer contains an average of 63 genetic alterations within a core set of 12 cellular signaling pathways, including the C-jun, invasion, and TGF-β pathways. In the present study, we found that nuclear transcription factor-related inflammatory cytokines were indeed regulated by oridonin treatment in pancreatic cancer cells.

NF-κB and AP-1 are pleiotropic transcription factors that are expressed in response to extracellular inflammation signals, such as IL-1β, and IL-33. NF-κB/Rel binding activity involves both NF-κB1 (p50) and RelA (p65). Previous studies support the idea that NF-κB plays important roles in cellular resistance to apoptosis, the promotion of tumor metastasis, and angiogenesis. The transcription factor NF-κB/Rel has been found to be constitutively activated in human pancreatic cancer and potentially activates epidermal growth factor receptor. In our previous study, inhibition of IKK activity induced cell apoptosis[19]. Moreover, after L3.3 cells transfected with mutated I kappa B alpha were implanted in the pancreas of nude mice, they produced rapidly growing tumors that metastasized to the liver[20]. C-Jun is a central component of all AP-1 complexes and is a positive regulator of cell proliferation[21]. Hypoxic environments up-regulate the IL-8 gene via cooperation between NF-κB and AP-1, which can be induced and can accumulate in the nucleus in hypoxic environments[22], thereby contributing to the progression and metastasis of human pancreatic cancer[23]. In this study, we found that NF-κB1, RelA, phospho-RelA, and AP-1 were down-regulated, suggesting that the NF-κB/AP-1 signaling pathway might be involved in the mechanism of oridonin-induced hallmark changes in BxPC-3 cell.

IL-33, a recently described member of the IL-1 family, is a dual-function protein that acts as both a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties[24]. Higher serum levels of IL-33 in patients with gastric cancer correlate with depth of invasion, distant metastasis and advanced stage (stage III/IV)[25]. Moreover, in patients with head and neck squamous cell carcinoma (HNSCC), most cases with a low invasion pattern grading score (IPGS) exhibit little to no IL-33 expression, whereas most HNSCC cases with a high IPGS exhibit IL-33 over-expression in cancer cells[26]. In addition, recent studies indicate that IL-33 is a chromatin-associated nuclear factor with transcriptional regulatory properties[27], such as binding to the p65 promoter region to participate in inflammatory reactions[28]. Moreover, IL-33 peptide can regulate chromatin compaction by promoting nucleosome-nucleosome interactions[29] and might regulate PDGF-induced proliferation in pancreatic stellate cells[30]. However, the function of
IL-33 as a nuclear factor is poorly defined in pancreatic cancer. In this study, we determined that the expression of extracellular or nuclear IL-33 is decreased by treatment with oridonin, suggesting that this compound can reduce IL-33-induced carcinogenesis in BxPC-3 cells. In our further study, the role of IL-33 in the regulation of BxPC-3 functions will be examined using recombinant IL-33 and small interfering RNA.

STAT3, a member of the Janus kinase (JAK)/STAT signaling pathway, is activated by the phosphorylation of a conserved tyrosine residue Tyr705 (P-STAT3) in response to extracellular signals, such as IL-6[12]. The abnormal activation of STAT3 participates in pancreatic cancer[28] and plays a critical role in oncogenesis, metastasis, and tumor growth. Inhibition of activated STAT3 decreases the level of cell cycle control factors such as p21, cyclin A, cyclin B1[27], and cyclin D1[29]. Additionally, this inhibition also decreases the expression of VEGF and MMP-2, factors that are related to cell metastasis. Also, STAT3 transcriptionally regulates the expression of anti-apoptotic proteins, such as Bcl-xL and survivin[29]. In this study, we found that the expression levels of IL-6, STAT3, and phospho-STAT3 are decreased by treatment with oridonin, suggesting that this compound can down-regulate the STAT3 signaling pathway, which is responsible for the hallmarks of growth, invasion, and metastasis of human pancreatic cancer. Type I interferons (IFNs) may have a possible role in the treatment of pancreatic adenocarcinoma, but the limitation of their clinical use is due to the activation of tumor resistance mechanisms, including the JAK2/STAT3 pathway[30,31]. In this light, oridonin provides a promising way of interfering with STAT-3 signaling, therefore, we cannot exclude the possibility of future use of oridonin in combination with some chemotherapeutic compounds in pancreatic cancer.

The TGFβ superfamily comprises TGFβs, BMPs, activins, and related proteins. TGFβs are pleiotropic factors that regulate cell proliferation, angiogenesis, metastasis, and immune suppression. Dysregulation of the TGFβ pathway in pancreatic cancer cells often leads to tumor invasiveness and growth. SD-208, a 2,4-disubstituted pteridine and an ATP-competitive inhibitor of TGFβ receptor I kinase (TGFβRI), has been used in PANC-1 cell line. cDNA microarray analysis and functional gene clustering identified groups of TGFβ-regulated genes that are involved in metastasis, angiogenesis, cell proliferation, survival, and apoptosis. The expression of these genes is inhibited by treatment with SD-208[32]. Additionally, Smads have different functions in pancreatic cancer cells. Smad1 induces and up-regulates MMP-2, stimulating pancreatic cancer cell invasiveness[33]. siRNA-mediated silencing of Smad3 in PANC-1 cells, a TGFβ-responsive pancreatic ductal adenocarcinoma cell line, decreased TGFβ1-induced growth inhibition but increased the migratory response; in contrast, silencing of Smad2 enhanced growth inhibition but decreased chemokinesis[34]. The tumor suppressor gene, Smad4/deleted in pancreatic carcinoma, locus 4, is lost at a high frequency in pancreatic cancer. Loss of Smad4, which leads to aberrant activation of STAT3, contributes to the switch of TGF-β from a tumor-suppressive to a tumor-promoting pathway in pancreatic cancer[35]. In one study, restoration of Smad4 expression in human pancreatic carcinoma cells suppressed tumor formation in vivo but was unable to restore sensitivity to TGF-β. Instead, Smad4 restoration affected angiogenesis by decreasing VEGF expression[36]. Smad7 is over-expressed in pancreatic cancer cell lines, enhancing growth inhibition but decreased chemokinesis[37]. Few reports are available regarding Smad6 expression in pancreatic cancer. Smad6 and Smad7 expression is elevated in pancreatic cancer and has been demonstrated to suppress TGFβ-induced growth inhibition in COLO-357 pancreatic cancer cells[38]. The present study also showed that oridonin down-regulates TGFβ1, BMP-2, Smad1/2/3/5/6/7, and Smad4 expression, suggesting that oridonin can beneficially revert the abnormal expression of Smads.

A better understanding of the relationship between neoplastic hallmarks and nuclear transcription factors will help us to interpret the novel mechanisms of oridonin-mediated decreases in cancer growth, angiogenesis, and metastasis. In conclusion, we have demonstrated that oridonin reduces growth, angiogenesis, and metastasis per-

Figure 5  Proposed mechanism of oridonin-induced hallmark changes in BxPC-3 cells. Oridonin induces anticancer actions, which reflected by hallmarks changes, through regulation of transcription factors.
hap through the regulation of inflammatory factors and downstream transcription factors (Figure 5). Oridonin therefore exhibits potential for use in the treatment of pancreatic cancer. Afterwards, we will focus on exploring its therapeutic effects, toxicity and the underlying mechanism in animal models of pancreatic cancer.

REFERENCES
1. Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. *Lancet* 2004; 363: 1049-1057 [PMID: 15301286 DOI: 10.1016/S0140-6736(04)6841-8]
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. *CA Cancer J Clin* 2008; 58: 72-20 [PMID: 18287387 DOI: 10.3322/CA.2007.00110]
3. Rebours V, Boutron-Ruault MC, Schnée M, Férec C, Maire F, Hammel P, Ruszniewski P, Lévy P. Risk of pancreatic adenocarcinoma in patients with hereditary pancreatitis: a national exhaustive series. *Am J Gastroenterol* 2008; 103: 111-119 [PMID: 18184119 DOI: 10.1111/j.1572-0241.2007.01597.x]
4. Ebrahim B, Tucker SL, Li D, Abbruzzese JL, Kurzrock R. Cytokines in pancreatic carcinomas: correlation with phenotypic characteristics and prognosis. *Cancer* 2004; 101: 2727-2736 [PMID: 15526319 DOI: 10.1002/cncr.20672]
5. Sun HD, Huang SX, Han QB. Diterpenoids from Isodon rubescens and inflammatory factors. *Zhejiang Zhongyiyao Da* Xuebao 2013; 5: 606-612
6. Chen S, Gao J, Halicka HD, Huang X, Traganos F, Darzynkiewicz Z. The cytostatic and cytotoxic effects of oridonin (Rubescenin), a diterpene from Rabdosia rubescens, on tumor cells of different lineage. *Int J Oncol* 2005; 25: 579-588 [PMID: 15703811 DOI: 10.3892/ijo.26.3.579]
7. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. *Nature* 2008; 454: 436-444 [PMID: 18659141 DOI: 10.1038/nature07205]
8. Rogers A, Smith MJ, Doolan P, Clarke C, Clynes M, Murphy JF, McDermott A, Swan N, Crotty P, Ridgepath WF, Conlon KC. Invasive markers identified by gene expression profiling in pancreatic cancer. *Pancreatology* 2012; 12: 150-160 [PMID: 22487523 DOI: 10.1016/j.pan.2011.12.011]
9. Schmiedler A, Multhoff G, Radons J. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells. *Cytokine* 2012; 60: 514-521 [PMID: 22891391 DOI: 10.1016/j.cytod.2012.06.286]
10. Denley SM, Jamieson NB, McCall P, Oien KA, Morton JP, Carter CR, Edwards J, McKay CJ. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. *J Gastrointest Surg* 2013; 17: 887-898 [PMID: 23435739 DOI: 10.1007/s11605-013-2168-7]
11. Jin X, Wu Y. Berbamine enhances the anti-angiogenic activity of gemcitabine in pancreatic cancer cells by activating transforming growth factor-β/Smad signaling. *Anticancer Res* (Hoboken) 2014; 297: 802-809 [PMID: 24619961 DOI: 10.1016/ arccancer.2012.08.228]
12. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolsky I, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Esheleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. *Science* 2008; 321: 1801-1806 [PMID: 18772397 DOI: 10.1126/science.1164368]
13. Liptay S, Weber CK, Ludwig L, Wagner M, Adler G, Schmid RM. Mitogenic and antiapoptotic role of constitutive NF-kappaB Rel activity in pancreatic cancer. *Int J Cancer* 2003; 105: 735-746 [PMID: 12767037 DOI: 10.1002/ijc.11801]
14. Xiong HQ, Abbruzzese JL, Lin E, Wang L, Zhang L, Xie K. NF-kappaB activity blockade impairs the angiogenic potential of human pancreatic cancer cells. *Int J Cancer* 2004; 108: 181-188 [PMID: 14639600 DOI: 10.1002/ijc.11562]
15. Shaullian E, Karin M. AP-1 as a regulator of cell life and death. *Nat Cell Biol* 2002; 4: E131-E136 [PMID: 11988788 DOI: 10.1038/ncb0502-6131]
16. Qi S, Le X, Abbruzzese JL, Wang B, Mujaida N, Matsushima K, Huang S, Xiong Q, Xie K. Cooperation between
transcription factor AP-1 and NF-kappaB in the induction of interleukin-8 in human pancreatic adenocarcinoma cells by hypoxia. J Interferon Cytokine Res 1999; 19: 1363-1371 [PMID: 10363870 DOI: 10.1089/107999099312821]

19 Le X, Shi Q, Wang B, Xiong Q, Qian C, Pong Z, Li XC, Tang H, Abbazzeese JL, Xie K. Molecular regulation of constitutive expression of interleukin-8 in human pancreatic adenocarcinoma. J Interferon Cytokine Res 2000; 20: 935-946 [PMID: 11096450 DOI: 10.1089/10799900050198372]

20 Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Gritsko T, Perrettie K, Ben Q, Tu S, Dong W, Qi X, Wu Y. Serum interleukin-33 levels in patients with gastric cancer. Dig Dis Sci 2011; 56: 3956-3601 [PMID: 21643739 DOI: 10.1007/s10620-011-1760-5]

21 Chen SF, Nieh S, Jao SW, Wu MZ, Liu CL, Chang YC, Lin YS. The paracrine effect of cancer-associated fibroblast-induced interleukin-33 regulates the invasiveness of head and neck squamous cell carcinoma. J Pathol 2013; 231: 180-189 [PMID: 23775566 DOI: 10.1002/path.4226]

22 Choi YS, Park JA, Kim J, Rho SS, Park H, Kim YM, Kwon YG. Nuclear IL-33 is a transcriptional regulator of NF-κB p65 and induces endothelial cell activation. Biochim Biophys Acta Commun 2012; 421: 305-311 [PMID: 22708120 DOI: 10.1016/j.bjbc.2012.04.005]

23 Roussel L, Erard M, Cayrol C, Girard JP. Molecular mimicry between IL-33 and KSHV for attachment to chromatin through the H2A-H2B acidic pocket. EMBO Rep 2008; 9: 1006-1012 [PMID: 18688256 DOI: 10.1038/embor.2008.145]

24 Masamune A, Watanabe T, Kikutaka K, Sato K, Kanno A, Amato GL, Shimossegawa T. Nuclear expression of interleukin-33 in pancreatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2010; 299: G821-G832 [PMID: 20669508 DOI: 10.1152/ajpgi.00178.2010]

25 Hutsen B, Willis W, Jones S, Gen L, Deangelis S, Fuh B, Lin J. Dietary agent, benzyl isothiocyanate inhibits signal transducer and activator of transcription 3 phosphorylation and inducer and activator of transcription 3 phosphorylation and collaboration with sulforaphane in the growth suppression of PANC-1 cancer cells. Cancer Cell Int 2009; 9: 24 [PMID: 19712481 DOI: 10.1186/1475-2867-9-24]

26 Pham NA, Schwock J, Jakovlev V, Pond G, Hedley DW, Tsa0 MS. Immunohistochemical analysis of changes in signaling pathway activation downstream of growth factor receptors in pancreatic ductal carcinoma. BMC Cancer 2008; 8: 43 [PMID: 18254976 DOI: 10.1186/1471-2407-8-43]

27 Toennis NH, Ivanowski GB, Doan NB, Okamoto R, Lin P, Abbassi S, Song JH, Yin D, Toh M, Xie WD, Said JW, Koeffler HP, Cuburkcin B induces apoptosis by inhibition of the JAK/STAT pathway and potentiates antiproliferative effects of gemcitabine on pancreatic cancer cells. Cancer Res 2009; 69: 5876-5884 [PMID: 19605406 DOI: 10.1158/0008-5472.CAN-09-0536]

28 Gritsko T, Williams A, Turkson J, Kaneko S, Bowman T, Huang M, Nam S, Eweis I, Diaz N, Sullivan D, Yoder S, En-kemann S, Eschrich S, Lee JH, Beam CA, Cheng J, Minton S, Muro-Cacho CA, Jove R. Persistent activation of stat3 signal ing induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin Cancer Res 2006; 12: 11-19 [PMID: 16397018 DOI: 10.1158/1078-0432.CCR-04-1752]

29 Dicitore A, Caraglia M, Gaudenzi G, Manfredi G, Amato B, Mari D, Persani L, Arra C, Vitale G. Type I interferon-mediated pathway interacts with peroxisome proliferator activated receptor-γ (PPAR-γ) at the cross-road of pancreatic cancer cell proliferation. Biochim Biophys Acta 2014; 1845: 42-52 [PMID: 24295667 DOI: 10.1016/j.bbacli.2013.11.003]
